$EWTX News
Last published 1d ago
- 1d agoEWTXGuggenheim 3rd Annual Healthcare Innovation Conference - EDGEWISE THERAPEUTICS INCEarnings Call TranscriptsMorning Guggenheim's third healthcare innovation conference. My name is Moritz I'm part of the therapeutics team and it's my privilege today to host Kevin Koch CEO of address therapeutics Kevin thank you so much for maki
- 2d agoEWTXEdgewise Therapeutics to Participate in Upcoming Investor ConferencesPR NewswireEdgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that management...
- 1w agoEWTXEdgewise Therapeutics, Inc. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1mo agoEWTXEdgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400PR Newswire– Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% –– EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human data to be presented at HFSA 2026 –BOULDER, Colo.,
- 1mo agoEWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireEdgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on...
- 1mo agoEWTXEdgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500PR NewswireEdgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced...
- 2mo agoEWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireEdgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on...
- 2mo agoEWTXEdgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026PR NewswireEdgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced...
- 3mo agoEWTXEdgewise Therapeutics Reports Second Quarter 2026 Financial ResultsPR NewswireEdgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported...
- 4mo agoEWTXEdgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular PipelinePR NewswireEdgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced...
- 4mo agoEWTXServier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy BusinessPR NewswireServier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the...
- 4mo agoEWTXServier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy BusinessPR NewswireServier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the...
- 4mo agoEWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireEdgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel...
- 4mo agoCRVOEWTXNTHISLBTBiotech Bulls Stampede as Clinical Wins and Milestones Fuel MomentumGlobeNewswireDENVER, June 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Multiple clinical-stage companies are delivering meaningful regulatory, clinical, and corporate milestones. From brain cancer drug development and cell
- 4mo agoEWTXEDG-7500 CIRRUS-HCM Update - EDGEWISE THERAPEUTICS INCEarnings Call TranscriptsThank you so much for joining us. Thank you. Thank you. We'll be right back. Thank you. Thank you. We'll see you next time. Alright, this is the Edgewise Therapeutics event. We are testing 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.
- 4mo agoEWTXEdgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)PR NewswireEdgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line results from the...
- 5mo agoEWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireEdgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel...
- 5mo agoEWTXEdgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular PipelinePR NewswireEdgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that it has entered into a definitive ...
- 5mo agoEWTXServier to Acquire Edgewise Therapeutics' Muscular Dystrophy BusinessPR NewswireServier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into an agreement to acquire ...
- 5mo agoEWTXServier to Acquire Edgewise Therapeutics' Muscular Dystrophy BusinessPR NewswireServier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into an agreement to acquire ...
- 6mo agoEWTXEdgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026PR NewswireEdgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present ...
- 6mo agoACHVEWTXORKAAchieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona PharmaGlobeNewswireSEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global
- 6mo agoEWTXEdgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular IndicationsPR NewswireEdgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first...
- 6mo agoEWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireEdgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel...
- 7mo agoEWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireEdgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel...
- 8mo agoEWTXEdgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-UpPR NewswireEdgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and...
- 8mo agoEWTXEdgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026PR NewswireEdgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present ...
- 8mo agoEWTXEdgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific ConferencePR NewswireEdgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 2026...
- 8mo agoEWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireEdgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel...
- 8mo agoEWTXEdgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular ProgramsPR NewswireEdgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth...
- 9mo agoEWTXEdgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026PR NewswireEdgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Behrad Derakhshan, Ph.D., Chief ...
- 9mo agoEWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireEdgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel...
- 10mo agoEWTXEdgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026PR NewswireEdgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided updates on the Company's clinical...
- 10mo agoEWTXEdgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026PR NewswireEdgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D., President...
- 10mo agoEWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireEdgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel...
- 10mo agoEWTXEdgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic CardiomyopathyPR NewswireEdgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical trial of EDG-7500, a...
- 11mo agoEWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireEdgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel...
- 11mo agoEWTXEdgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of DirectorsPR NewswireEdgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology...
- 12mo agoEWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireEdgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel...
- 1y agoEWTXEdgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael CarruthersPR NewswireEdgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular...
- 1y agoEWTXEdgewise Therapeutics to Participate in Upcoming Investor ConferencesPR NewswireEdgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in...
- 1y agoEWTXEdgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsPR NewswireEdgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third...
- 1y agoEWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireEdgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel...
- 1y agoEWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireEdgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel...
- 1y agoEWTXEdgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle SocietyPR NewswireEdgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 30th...
- 1y agoEWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireEdgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel...
- 1y agoEWTXEdgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsPR NewswireEdgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the second...
- 1y agoEWTXEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireEdgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel...
- 1y agoEWTXEdgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular DystrophiesPR NewswireEdgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today unveiled positive results in its sevasemten...
- 1y agoEWTXEdgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare ConferencePR NewswireEdgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the...